CXCR4 chemokine receptor signaling mediates pain in diabetic neuropathy
© Menichella et al.; licensee BioMed Central Ltd. 2014
Received: 14 June 2013
Accepted: 18 June 2014
Published: 25 June 2014
Painful Diabetic Neuropathy (PDN) is a debilitating syndrome present in a quarter of diabetic patients that has a substantial impact on their quality of life. Despite this significant prevalence and impact, current therapies for PDN are only partially effective. Moreover, the cellular mechanisms underlying PDN are not well understood. Neuropathic pain is caused by a variety of phenomena including sustained excitability in sensory neurons that reduces the pain threshold so that pain is produced in the absence of appropriate stimuli. Chemokine signaling has been implicated in the pathogenesis of neuropathic pain in a variety of animal models. We therefore tested the hypothesis that chemokine signaling mediates DRG neuronal hyperexcitability in association with PDN.
We demonstrated that intraperitoneal administration of the specific CXCR4 antagonist AMD3100 reversed PDN in two animal models of type II diabetes. Furthermore DRG sensory neurons acutely isolated from diabetic mice displayed enhanced SDF-1 induced calcium responses. Moreover, we demonstrated that CXCR4 receptors are expressed by a subset of DRG sensory neurons. Finally, we observed numerous CXCR4 expressing inflammatory cells infiltrating into the DRG of diabetic mice.
These data suggest that CXCR4/SDF-1 signaling mediates enhanced calcium influx and excitability in DRG neurons responsible for PDN. Simultaneously, CXCR4/SDF-1 signaling may coordinate inflammation in diabetic DRG that could contribute to the development of pain in diabetes. Therefore, targeting CXCR4 chemokine receptors may represent a novel intervention for treating PDN.
KeywordsChemokine Neuropathic pain Painful diabetic neuropathy DRG neurons
Neuropathic pain in diabetes, Painful Diabetic Neuropathy (PDN), is a debilitating affliction present in 26% of diabetic patients [1–3] with substantial impact on their quality of life . Despite this significant prevalence and impact, current therapies for PDN are only partially effective. Moreover, the molecular and electrophysiological mechanisms underlying PDN are not well understood.
This lack of understanding of the pathogenesis and the molecular mechanisms underlying neuropathic pain represents a barrier to further progress in this field as emphasized by the failure of numerous potential therapeutic approaches to successfully treat PDN. Opiates are not particularly effective in treating neuropathic pain and given the chronic nature of this syndrome their use is problematic . Other drugs, such as gabapentinoids and antidepressants, do produce limited relief in some patients but the presence of significant side effects and their lack of effectiveness in many patients [5, 6] means that better therapeutic approaches are urgently needed. Given the prevalence of PDN and the absence of effective therapies we wanted to elucidate the molecular and physiological mechanisms responsible for PDN as a critical step towards developing more effective targeted therapeutic interventions in this disorder.
Pain is a physiological response to potentially dangerous noxious stimuli. However, pathological or “neuropathic pain” is associated with sustained excitability of sensory neurons within pain pathways leading to reduced nociceptive thresholds and the development of pathological spontaneous activity, so that pain is produced in the absence of appropriate stimuli [7–9]. The molecular mechanisms responsible for abnormal excitability in sensory neurons leading to neuropathic pain are mostly unknown. However, Dorsal Root Ganglia (DRG) sensory neurons develop pathological spontaneous activity in response to different molecules such as inflammatory cytokines and chemokines [10–14].
Chemokines, or chemotactic cytokines, are a large group of proteins important for the regulation of leukocyte migration [15, 16]. In the last decade, numerous studies have demonstrated that, in addition to their role in coordinating the immune response, chemokines have important functions in the nervous system . For example, excitatory chemokine signaling has been implicated in the pathogenesis of neuropathic pain in several animal models . In particular, some reports have implicated the chemokine stromal cell derived factor 1 (SDF-1) and its receptor CXCR4 in the pathogenesis of neuropathic pain in a subset of animal models including HIV-1 induced neuropathy [19, 20] and opiate induced hyperalgesia . Importantly, CXCR4 receptor expression as measured by microarray analysis was increased in peripheral nerve samples from diabetic patients with progressive diabetic neuropathy , suggesting a similar role for CXCR4 receptors in PDN.
Based on this evidence, we hypothesized that excitatory CXCR4/SDF-1 signaling in DRG neurons may play a critical role in the pathogenesis of PDN.
We now demonstrate that administration of a selective CXCR4 antagonist, AMD3100, substantially reverses neuropathic pain in animal models of type II diabetes. These results indicate that CXCR4 mediated signaling is necessary for PDN in mice. This hypothesis is consistent with the expression of CXCR4 by a subpopulation of DRG neurons and increased excitatory effects of the chemokine SDF-1 on diabetic DRG neurons in culture. Additionally, we observed numerous CXCR4 expressing inflammatory cells infiltrating the DRG of diabetic mice.
Overall, these data suggest that CXCR4/SDF-1 signaling mediates enhanced calcium influx and excitability in DRG neurons responsible for PDN. CXCR4/SDF-1 signaling may simultaneously coordinate inflammation in diabetic DRG that could contribute to the development of pain in diabetes. Therefore, CXCR4 signaling may constitute a novel target for therapeutic intervention to PDN.
The specific CXCR4 antagonist AMD3100 reverses neuropathic pain in two animal models of type-II diabetes
Glucose tolerance test (GTT) and weight of wild-type mice on high-fat-diet (WT HFD) and wild-type mice on regular diet (WT RD)
Fasting glucose (mg/dl)
30 mins GTT (mg/dl)
60 mins GTT (mg/dl)
120 mins GTT (mg/dl)
34.0 +/− 0.8
112.2 +/− 4.7
465.1 +/− 13.9
444.9 +/− 18.0
264.7 +/− 14.0
26.9 +/− 0.4
89.3 +/− 4.4
217.0 +/− 17.9
188.5 +/− 4.4
161.3 +/− 8.5
In order to determine whether SDF-1/CXCR4 signaling played a role in this behavior we examined the effects of blocking CXCR4 receptors on pain behavior in this model of type II diabetes. The highly selective CXCR4 chemokine receptor antagonist AMD3100 was administered at a concentration of 5 mg/kg, given as a single intraperitoneal (i.p.) injection. We elected to use this concentration of AMD3100 as we have previously demonstrated it to be effective in other animal models of neuropathic pain [19, 20]. Von Frey behavioral studies for mechanical allodynia were repeated at 2 and 24 hours after AMD 3100 administration. These times points were elected as we had already demonstrated that AMD3100 effectively reversed neuropathic pain in other animal models one hour after intraperitoneal injection [19, 20].
These experiments demonstrated that AMD3100 substantially reversed neuropathic pain in HFD diabetic mice. Indeed, 2 hours after antagonist injection in HFD diabetic mice the paw withdrawal threshold increased significantly compared with HFD induced diabetic mouse injected with saline. Statistical analysis revealed that the 50% threshold was 1.001 g with SE 0.07 in HFD diabetic mice injected with ADM3100 (n = 8) compared to 0.157 g with SE 0.013 in HFD diabetic mice injected with saline (n = 8). Values are expressed as means +/− SE (p <0.001) (Figure 1A). After 24 hours this effect was no longer apparent (Figure 1A). In contrast a selective CCR2 chemokine receptor blocking drug only minimally reversed allodynia in HFD induced diabetic mice. Statistical analysis revealed that the 50% threshold was 0.302 g with SE 0.024 in HFD diabetic mice injected with CCR2 antagonist (n = 6) compared to 0.174 g with SE 0.019 in HFD diabetic mice injected with saline (n = 8). Values are expressed as means +/− SE (p <0.001). This result differs from some other pain models our laboratory has investigated such as in osteoarthritis where CCR2 receptor deletion or CCR2 receptor antagonists are much more effective in ameliorating pain .
In order to confirm our findings in an additional model of type II diabetes we repeated the same set of experiments in a second well characterized model in which mice carry a leptin receptor null mutation: the C57BLKS db/db (db/db) mouse line. Db/db mice are known to display mechanical allodynia after 6 weeks of age . In keeping with these previous reports, we observed that 18 weeks old homozygous db/db mice displayed tactile allodynia (Figure 1B). Von Frey behavioral studies for mechanical allodynia were repeated at 2 and 24 hours after AMD3100 administration at a concentration of 5 mg/kg, given as a single intraperitoneal injection (i.p.). These experiments demonstrated that AMD3100 also substantially reversed neuropathic pain in homozygous db/db mice at 2 but not 24 hours after administration of the drug. Statistical analysis revealed that the 50% threshold was 1.637 g with SE 0.084 in db/db injected with AMD3100 (n = 8) compared with 0.320 g with SE 0.021 in db/db mice injected with saline (n = 8). Values are expressed as means +/− SE (p <0.001) (Figure 1B).
Overall this first series of experiments demonstrated that SDF-1/CXCR4 signaling is necessary for the expression of pain hypersensitivity in two separate animal models of type II diabetes. As a result of these observations we next wanted to investigate the status of excitatory CXCR4/SDF-1 signaling in DRG neurons taken from diabetic animals.
Enhanced SDF-1 induced increases in intracellular calcium concentrations [Ca2+]i in HFD induced diabetic DRG neurons
These results indicate that a increased number DRG neurons express functional CXCR4 receptors in diabetic mice and suggest that increased excitatory CXCR4/SDF-1 signaling in DRG neurons could contribute to PDN.
CXCR4/SDF-1 signaling in diabetic DRG sensory neurons
We also examined the state of SDF-1 expression in the DRG from normal and diabetic animals. We elected to assess SDF-1 expression using mice expressing an SDF-1-mRFP transgene generated in our laboratory . Using an antibody against mRFP, we observed that DRG neurons from HFD diabetic SDF-1-mRFP mice greatly increased their expression of SDF-1 (Figure 4D and E) compared to DRG neurons from RD mice (Figure 4F) (quantification in figure legend, Figure 4D-F).
Hence, SDF-1 released from DRG neurons would be an ideal position to activate excitatory CXCR4 receptors expressed by DRG neurons in PDN.
Inflammatory cell infiltration into diabetic DRG
The presence of CXCR4 expressing immune cells with the prevalence of CD3 positive T-cells in diabetic DRG may have important implications for the generation of pain in diabetes.
All animal experiments were approved by the Institutional Animal Care and Use Committee at Northwestern University. Animals were housed with food and water ad libitum and kept on 12-hours light cycle. Wild-type 8 weeks-old male C57BL/6 (Jackson Laboratories), 18 weeks old db-db homozygous mice (Homozygous Lepr db, BKS.Cg-Dock7 m −/− Lepr db /J, Jackson Laboratories), 18 weeks old heterozygous mice (Heterozygous Lepr db, BKS.Cg-Dock7 m +/− Lepr db /J, Jackson Laboratories), 8 weeks old CXCR-4 eGFP mice and SDF-1-mRFP mice, generated in our laboratory , were used in these studies.
High Fat Diet (HFD)-induced diabetes as a model of Diabetes type II
HFD induces insulin resistance and is therefore used to create rodent models of diabetes type-II . Wild-type 8 weeks-old male C57BL/6 mice, CXCR-4 eGFP mice and SDF-1-mRFP mice were fed with a 42% fat diet for 10 weeks. Control mice were fed with regular diet (11% fat diet). After 10 weeks on HFD, Glucose Tolerance Test (GTT) was performed as previously described . Briefly, mice, after fasting for 12 hours, were injected with a 45% D-glucose solution (2mg glucose/1g animal body weight). Blood glucose is measured immediately before and 30, 60, and 120 minutes after glucose injection using an OneTouch UltraMini glucose meter and OneTouch Ultra test strips.
Von Frey behavioral studies were performed as previously described [9, 19, 20, 33, 34]. Briefly, mice were placed on a metal mesh floor and covered with a transparent plastic dome where the animal rested quietly after an initial few minutes of exploration. Animals were habituated to this testing apparatus for 15 minutes a day, two days prior to pre-injection behavioral testing. Following acclimation, each filament was applied to the glabrous side of the hind paw. Mechanical stimuli were applied with seven filaments, each differing in the bending force delivered (10, 20, 40, 60, 80, 100, and 120 mN), but each fitted a flat tip and a fixed diameter of 0.2 mm. The force equivalence of mN to grams is: 100 mN = 10.197 grams. The filaments were tested in order of ascending force, with each filament delivered for 1 second. The interstimulus interval was 10–15 seconds .
The incidence of foot withdrawal was expressed as a percentage of six applications of each filament as a function of force. A Hill equation was fitted to the function (Origin version 6.0, Microcal Software) relating the percentage of indentations eliciting a withdrawal to the force of indentation. From this equation, the threshold force was obtained and defined as the force corresponding to a 50% withdrawal rate . The GB-Stat School Pack software (Dynamic Microsystem) was used to statistically evaluate all data. The one-way analysis of variance (ANOVA) with a Dunnett’s Multiple Comparison test was used to analyze difference between multiple experimental groups. A probability level of .05 indicates significance.
CXCR4 chemokine receptor blocker administration
The highly specific CXCR4 antagonist, AMD3100 (Sigma (St Louis, MO, USA), was used for the all the experiments. The CXCR4 chemokine receptor antagonist was administered to HFD induced diabetic and control non-diabetic mice 10 weeks after diet, to 18 weeks old diabetic homozygous C57BLKS db/db (db/db) mice and control heterozygous C57BLKS db/db (db het) mice. The drug was freshly prepared in saline on the day of the experiment at a concentration of 5 mg/kg and given as a one-time intraperitoneal (i.p.) injection.
Preparation of acutely cultured dorsal root ganglion neurons
DRG sensory neurons from HFD-induced diabetic wild-type mice were acutely dissociated as previously described  after 10 weeks of HFD. Wild type mice on regular diet were used as controls. Briefly, DRG neurons were acutely dissociated via collagenase 4 (1 μg/ml) and papain (30 U/ml), Worthington Biochemical Corp, Lakewood, NJ) digestion. Cells were plated on poly-L-lysine and laminin (20 μg/ml) coated glass coverslips and cultured at 37 degrees Celsius with 5% CO2, for 48 hrs in adult neurogenic medium: F12 with L-glutamine, 0.5% FBS, 1xN2 (Life Techonologies), penicillin (100 μg/ml) and streptomycin (100 U/ml).
Intracellular calcium imaging in vitro
The response of acutely cultured DRG neurons to the chemokines SDF-1 and MCP-1 (500 ng/ml R&D Systems) were recorded using intracellular calcium imagining following a standard protocol previously used in our laboratory . Briefly, acutely cultured DRG cells were loaded with fura-2 AM (3uM, Invitrogen, Carlsbad, CA) for 25 minutes at room temperature in a balanced salt solution (BSS) [NaCl (140 mM), Hepes (10 mM), CaCl2 (2 mM), MgCl2 (1 mM), Glucose (10 mM), KCl (5 mM)]. The cells were rinsed with the BSS and mounted onto a chamber that was placed onto the inverted microscope and continuously perfused with BSS at a rate of 2 ml/min. Intracellular calcium ([Ca2+]i) was measured by digital video microfluorometry with an intensified CCD camera coupled to a microscope and MetaFluor software. Cells were illuminated with a 150W xenon arc lamp, and the excitation wavelengths of the fura-2 (340/380 nm) were selected by a filter changer. Chemokines were applied for two minutes directly into the coverslip bathing solution after the perfusion was stopped. If no response was seen within 1 minute, the chemokine was washed out. For all experiments, SDF-1 (500 ng/ml, R&D Systems) and MCP-1 (500 ng/ml, R&D Systems), capsaicin (100 nM), high K + (50 mM) and ATP (100 μM) were added to the cells.
The significance of differences between the control group, and the various treatment groups were statistically analyzed. Within each treatment group, post-drug administration means were compared with the baseline/control values by analysis of variance (ANOVA).
Immunohistochemical labeling: Immunofluorescence
Adult CXCR4-eGFP mice were deeply anesthetized with isoflurane and transcardially perfused with saline followed by 4% paraformaldehyde. Lumbar ganglia were removed and post fixed for 4 hours. Sagittal sections of the DRG were serially cut at 20 μm onto Super Frost microscope slides (Fisher Scientific, Pittsburgh PA). At least 6 sections were obtained for immunocytological analysis per DRG. Slides were incubated with blocking buffer (3% BSA/3% horse serum/0.4% Triton-X; Fisher Scientific, Pittsburgh PA) for 1 hour, followed by overnight incubation with primary antibody. We used the following antibodies on CXCR4-eGFP DRG section: I-isolectin B4 (IB4-conjugated 647 from Invitrogen, used at 1:100 dilution) and Calcitonin gene-related peptide (CGRP rabbit polyclonal Ab from Abcam, used at 1:4000). Slides were washed in PBS three times for 5 minutes each and cover slipped with a Vectasheld.
Tissue sections were analyzed by confocal microscopy for co-expression of CXCR4 chemokine receptor eGFP and Isolectin (IB4) or Calcitonin gene-related peptide (CGRP) using confocal microscopy.
The proportions of immune-reactive neurons were determined from the total number of CXCR4-eGFP positive neuron present in a tissue section. At least 5000 neuronal profiles from six animals (minimum of 625 cells per ganglia) were quantified for each cell type in the single neuronal marker study and for each combination of cellular markers. Data are represented as means ± SE%.
Peroxidase-diaminobenzidine (DAB) immunolabeling
Wild-type 8 weeks-old male C57BL/6 mice and 8 weeks-old male SDF-1-mRFP mice, HFD-induced diabetic and control RD non-diabetic mice were deeply anesthetized with isoflurane and trans-cardially perfused with saline followed by 4% paraformaldehyde. Lumbar ganglia were removed and post fixed for 4 hours. Sagittal sections of the DRG were serially cut at 20 μm onto Super Frost microscope slides (Fisher Scientific, Pittsburgh PA). At least 6 sections were obtained for immune-cytological analysis per DRG. Sections were incubated with 3% hydrogen peroxidase for 30 minutes at room temperature to block endogenous peroxidase. Slides were then incubated with blocking buffer (5% donkey serum) for 1 hour, followed by overnight incubation with primary antibody. We used the following antibodies on DRG sections: anti-CD3 rabbit polyclonal antibody from Dako, used at 1:500; anti-CD68 rabbit polyclonal antibody from Abcam, used at 1:500; anti-F4/80 rat antibody from eBiosciences, used at 1:500 and anti-B220 rat antibody from BD Biosciences, used at 1:1000. Slides were washed three times in PBS for 5 minutes each and then incubated with secondary biotinylated antibody for 1 hour at room temperature. Colorimetric reaction was carried out using the ABC kit and streptavidin-HRP and DAB system from Vector Laboratories. Additionally, we used antibodies against RFP on DRG from SDF-1-RFP mice to detect chemokine SDF-1 (anti-RFP rabbit polyclonal Ab from Abcam, used at 1:1000). In this set of experiments, the colorimetric reaction was carried out using SG blue (Sk-4700), by Vector Laboratories.
The images of stained tissues were captured on a BX51 Olympus microscope using a 20x and 40x objectives with an Olympus DP70 digital camera controlled by analysis software (Soft Imaging System). Image acquisition was performed with the following fixed color settings: red = 0.36, green = 0.92, blue = 0.85, offset = 504, and exposure time of 6.8 milliseconds. At least 10 sections were analyzed from each mouse (3 HFD diabetic mice and 3 RD control mice). Counts were performed on a standardized area of 200 μm x 300 μm. The one-way analysis of variance (ANOVA) test was used to analyze difference between experimental groups. A probability level of .05 indicates significance.
In situ hybridization
In situ hybridization for chemokine receptor CXCR4 mRNA was performed using digoxigenin labeled riboprobes. Wild-type 8 weeks-old male C57BL/6 (Jackson Laboratories) HFD induced diabetic and RD non diabetic DRGs were rapidly removed, embedded in OCT compound (Tissue Tek, Ted Pella, Inc., Redding, CA) and frozen. Sections were cut serially at 12 μm. The CXCR4 probe was generated as described previously [19, 20]. Briefly, the rat CXCR4 cDNA was cloned as described [19, 20] and a 870-bp Sac I/Cla I fragment from CXCR4/pcDNA3.1 construct was used as CXCR4 riboprobe, which can cross-react with mouse CXCR4. The template was linearized with XbaI to generate an antisense probe by using SP6 polymerase. The sense probe was linearized with HindIII by using T7 polymerase. In situ hybridization for CXCR4 mRNA was performed by using digoxigenin-labeled riboprobes (Roche Applied Science), as previously describe [19, 20].
The images of stained tissues were captured on a BX51 Olympus microscope using a 20x and 40x objectives with an Olympus DP70 digital camera controlled by analysis software (Soft Imaging System). Image acquisition was performed with the following fixed color settings: red = 0.36, green = 0.92, blue = 0.85, offset = 504, and exposure time of 6.8 milliseconds. At least 10 sections were analyzed from each mouse (3 HFD diabetic mice and 3 RD control mice). Counts were performed on a standardized area of 200 μm × 300 μm. Experiments were carried out in duplicates. The one-way analysis of variance (ANOVA) test was used to analyze difference between experimental groups. A probability level of .05 indicates significance.
CXCR4/SDF-1 signaling has been implicated in the pathogenesis of neuropathic pain in a subset of animal models as illustrated in previous reports from our own and other laboratories [19, 20]. Importantly, CXCR4 expression is increased in a peripheral nerve microarray analysis from diabetic patients with progressive diabetic neuropathy , implicating CXCR4/SDF-1 signaling in the pathogenesis of diabetic neuropathy in humans. The present studies were designed to investigate a potential role for CXCR4/SDF-1 signaling in the pathogenesis of PDN. Indeed, we observed that the specific CXCR4 antagonist AMD3100 reversed PDN in two animal models of type II diabetes indicating that ongoing CXCR4/SDF-1 signaling is necessary for the manifestation of PDN. Furthermore, SDF-1 increased [Ca2+]i in DRG neurons from diabetic mice to a greater extent than in normal mice, suggesting increased CXCR4 receptor signaling in DRG neurons in the context of PDN. SDF-1 has also been shown to promote inflammatory cell infiltration into the DRG [10, 30]. Indeed, we observed increased SDF-1 expression in DRG neurons and a massive influx of inflammatory cells into the DRG of diabetic animals that may have important implications for the generation of pain behaviors under these circumstances. Overall these results suggest that CXCR4/SDF-1 signaling plays a critical role in the pathogenesis of PDN by inducing excitatory effects on DRG neurons and recruiting inflammatory cells into diabetic DRG.
The present studies demonstrate for the first time that excitatory CXCR4/SDF-1 signaling in DRG neurons plays a critical role in the pathogenesis of PDN. Previous studies from our laboratory and others have demonstrated that SDF-1 and other chemokines can directly excite DRG neurons [20, 25, 29, 35, 36]. The pronociceptive effects of chemokines and their receptors include the induction of hyperexcitability of neurons through transactivation of transient receptor potential cation channel subfamily V member 1 (TRPV1) and other ion channels [37, 38]. This process has been demonstrated on cultured and previously injured adult DRG sensory neurons [37, 38]. We have now demonstrated that the specific CXCR4 antagonist AMD3100 reversed PDN in two animal models of type II diabetes indicating that ongoing CXCR4/SDF-1 signaling is necessary for the manifestation of PDN. As activation of CXCR4 chemokine receptors expressed by DRG neurons produces excitation , it is likely ongoing activation of CXCR4 receptors by SDF-1 released within the DRG contributes to the ectopic excitability of these neurons and produces AMD3100 reversible tactile hyperalgesia.
[Ca2+]i imaging experiments clearly demonstrated increased calcium mobilization in response to SDF-1 in cultured diabetic DRG neurons compared non diabetic control animals. Our laboratory and others have previously shown that activation of CXCR4 receptors by its ligand SDF-1 excites DRG neurons. Increased [Ca2+] i can be used as a readout of DRG neuron hyperexcitability in animal models of neuropathic pain [20, 25, 36]. Therefore, these data are consistent with the possibility that CXCR4/SDF-1 signaling plays a critical role in the pathogenesis of PDN by inducing excitatory effects directly on DRG neurons. Additionally, these data provide evidence of a considerable degree of CXCR4 receptor upregulation in acutely cultured diabetic DRG neurons. Interestingly, however, we actually observed a decline in CXCR4 gene transcriptional activity in vivo in diabetic CXCR4-eGFP mice. These results appear to contradict one another. However, an explanation was provided by further studies using in situ hybridization to detect CXCR4 mRNA expression in the DRG. We observed two types of CXCR4 expressing neurons in the DRG of normal mice. One population expressed very high levels of CXCR4 mRNA and the other group expressed lower levels. In diabetic mice we observed that the population of neurons that expressed very high levels of CXCR4 receptors was greatly reduced. In contrast the total number of neurons expressing CXCR4 receptors was increased. It is likely that we are only able to detect the population of neurons with high levels of CXCR4 expression using CXCR4-eGFP transgenic mice. This would explain why the number of CXCR4-eGFP cells is found to be reduced in diabetic CXCR4-eGFP transgenic mice, but we detect an increased number of cells expressing functional CXCR4 receptors using in situ hybridization experiments and [Ca2+]i imaging assays. The reason for this overall shift in the pattern of DRG neurons expressing CXCR4 receptors in diabetic mice is elusive at this point. However, we did note that DRG neurons from diabetic mice exhibited greatly increased levels of SDF-1.
We have demonstrated that SDF-1 can be released from DRG neurons [10, 21]. Hence SDF-1 would be in a position to activate CXCR4 receptors expressed within the DRG of diabetic mice, which would be predicted to increase their excitability. Therefore it is possible that up-regulated expression of excitatory CXCR4 signaling within the DRG might be one factor driving increased excitability of these neurons in PDN.
Overall, these results are particularly interesting in light of recent publications using gene arrays to profile sural nerve samples from PDN patients, which reported that CXCR4 chemokine receptor expression was up-regulated in these samples . Hence, the data from both mice and humans suggests the presence of up-regulated excitatory CXCR4 signaling by DRG neurons in association with PDN. These observations raise questions that now need further investigation, for example to determine which subtypes of sensory neurons are the major elements responsible for SDF-1/CXCR4 mediated neuropathic pain in diabetes.
During embryonic development DRG sensory neurons differentiate into three primary subtypes: nociceptors, mechanoreceptors and proprioceptors. In the DRG, these are characterized by the expression of the neurotrophin receptors TrkA, TrkB and TrkC, respectively . During perinatal development nociceptors further differentiate into peptidergic (CGRP positive) and non-peptidergic (IB4 positive) . We demonstrated that high levels of CXCR4 receptors, as determined using CXCR4-eGFP mice, were selectively expressed by IB4 positive nociceptive neurons. This observation is of particular interest in light of prior publications demonstrating that peripheral inflammation selectively increases TRPV1 function in IB4 positive sensory neurons in mouse models of neuropathic pain [40, 41]. The enhanced responsiveness of IB4 binding neurons in the setting of inflammatory hyperalgesia could be mediated by CXCR4/SDF-1 signaling and be relevant in the pathogenesis of PDN. Our in situ hybridization studies also revealed the existence of a second population of DRG neurons, which express lower levels of CXCR4 receptors although we did not identify the properties of this neuronal subtype. Nevertheless, excitatory effects of CXCR4 activation in these neurons may also contribute to pain in diabetic mice.
In addition to their pronociceptive effects on DRG neurons chemokines and their receptors are important in the recruitment of leukocytes. The observed recruitment of numerous inflammatory cells into diabetic DRG suggests a critical role for inflammation in the pathogenesis of PDN. Immune cells can certainly secrete numerous algogenic factors, which may also have direct excitatory effects on DRG neurons or may sensitize DRG neurons to the excitatory effects of SDF-1 or other mediators [10, 14]. SDF-1 has been shown to promote inflammatory cell infiltration into the DRG [10, 30]. Hence SDF-1 released from diabetic DRG neurons may well influence the influx of inflammatory cells into DRG which may have important implications for the generation of pain behaviors under these circumstances.
The role of inflammation in the pathogenesis of PDN has been proposed elsewhere . Specifically, inflammatory cytokines such as interleukins IL-6, IL-2, and tumor necrosis factor-α (TNF-α) are elevated in hyperglycemia, suggesting that a chronic low grade inflammatory state exists in patients with diabetes [43, 44]. It has been observed that diabetic patients with higher plasma levels of TNF-α have a greater risk of developing PDN [43, 45, 46]. Moreover, compared with diabetic patients who have painless neuropathy those with PDN have been shown to have higher levels of C-reactive protein, considered to be a biomarker for any inflammatory process . Recently, inflammatory mediators, including TNF-α, interleukin-1, 6, 13 and 17, chemokines such as MIP-1α, RANTES and fractalkine, have been found to be increased in the DRG of Zucker diabetic fatty (ZDF) rats, an established model for type II diabetes . Additionally, molecules generated as the result of hyperglycemia including Advanced Glycolation End Products (AGE) and their receptor (RAGE) are considered important in the pathogenesis of PDN [49–52] and have been implicated in signaling pathways that induce transcription of proinflammatory genes . In particular, chemokine expression is one important downstream target for both TNF-α and RAGE signaling. The present study provides additional support for a role of inflammation in the pathogenesis PDN providing a novel theoretical concept and also a new therapeutic target for the treatment of PDN.
In conclusion, these studies establish CXCR4/SDF-1 chemokine signaling as a new candidate responsible for the manifestation of PDN. The data suggest a mechanism as to how ongoing sensory neuron excitability could be increased in order to induce and maintain neuropathic pain in diabetes. This concept is that chemokine signaling has a fundamental role in in producing increased excitability of sensory neurons during the transition from physiological to neuropathic pain in diabetes, as well as its subsequent maintenance. This is something that has not been previously appreciated with respect to PDN. Furthermore, SDF-1 could potentially play a crucial role in both recruiting inflammatory cells and producing direct excitatory effects on DRG neurons thereby coordinating the interaction between peripheral neurons and immune cells. Hence, targeting CXCR4/SDF-1 signaling may lead to advanced therapeutic approaches for the treatment of PDN. This novel and more targeted therapeutic intervention has advantages over existing and currently available therapeutic approaches which aim only to reduce symptoms generally by suppressing neuronal activity and are not particularly effective. In contrast, modulation of proalgesic chemokine signaling provides an opportunity for disease modification by inhibiting inflammatory process and neurobiological alterations that support the development of persistent pain.
This work was supported by the NIH grant 5 R25NS070694-04 Research Education Program for Trainees in Neurology (DMM), by the Dixon Young Investigator Grant: Northwestern Memorial Foundation (DMM), by the Northwestern University Mouse Histology and Phenotyping Laboratory and a Cancer Center Support Grant (NCI CA060553) and by the NIH K08 NS079482-01 (DMM). NIH 5R01DA013141-14 (RJM) and NIH/Rush University Medical Center 1R01AR064251-01 (RJM).
- American Diabetes A: Diagnosis and classification of diabetes mellitus. Diabetes Care 2011,34(Suppl 1):S62-S69.View Article
- Dyck PJ, Kratz KM, Lehman KA, Karnes JL, Melton LJ 3rd, O'Brien PC, Litchy WJ, Windebank AJ, Smith BE, Low PA: The Rochester Diabetic Neuropathy Study: design, criteria for types of neuropathy, selection bias, and reproducibility of neuropathic tests. Neurology 1991,41(6):799–807.PubMedView Article
- Spallone V, Lacerenza M, Rossi A, Sicuteri R, Marchettini P: Painful diabetic polyneuropathy: approach to diagnosis and management. Clin J Pain 2012,28(8):726–743.PubMedView Article
- DiBonaventura M, Cappelleri JC, Joshi AV: longitudinal assessment of painful diabetic peripheral neuropathy on health status, productivity, and health care utilization and cost. Pain Med 2011,12(1):118–126.View Article
- Bril V, England J, Franklin GM, Backonja M, Cohen J, Del Toro D, Feldman E, Iverson DJ, Perkins B, Russell JW, Zochodne DW: Evidence-based guideline: Treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology 2011,76(20):1758–1765.PubMed CentralPubMedView Article
- Quilici S, Chancellor J, Lothgren M, Simon D, Said G, Le TK, Garcia-Cebrian A, Monz B: Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain. BMC Neurol 2009, 9: 6.PubMed CentralPubMedView Article
- Latremoliere A, Woolf CJ: Central sensitization: a generator of pain hypersensitivity by central neural plasticity. J Pain 2009,10(9):895–926.PubMed CentralPubMedView Article
- von Hehn CA, Baron R, Woolf CJ: Deconstructing the neuropathic pain phenotype to reveal neural mechanisms. Neuron 2012,73(4):638–652.PubMed CentralPubMedView Article
- Zhang JM, Song XJ, LaMotte RH: Enhanced excitability of sensory neurons in rats with cutaneous hyperalgesia produced by chronic compression of the dorsal root ganglion. J Neurophysiol 1999,82(6):3359–3366.PubMed
- White FA, Bhangoo SK, Miller RJ: Chemokines: integrators of pain and inflammation. Nat Rev Drug Discov 2005,4(10):834–844.PubMed CentralPubMedView Article
- Miller RJ, Jung H, Bhangoo SK, White FA: Cytokine and chemokine regulation of sensory neuron function. Handbook Exp Pharmacol 2009, 194: 417–449.View Article
- Bautista DM, Jordt SE, Nikai T, Tsuruda PR, Read AJ, Poblete J, Yamoah EN, Basbaum AI, Julius D: TRPA1 mediates the inflammatory actions of environmental irritants and proalgesic agents. Cell 2006,124(6):1269–1282.PubMedView Article
- Abbadie C: Chemokines, chemokine receptors and pain. Trends Immunol 2005,26(10):529–534.PubMedView Article
- Uceyler N, Schafers M, Sommer C: Mode of action of cytokines on nociceptive neurons. Experimental brain research Experimentelle Hirnforschung Experimentation cerebrale 2009,196(1):67–78.PubMedView Article
- Zlotnik A, Yoshie O: Chemokines: a new classification system and their role in immunity. Immunity 2000,12(2):121–127.PubMedView Article
- Romano M, Sironi M, Toniatti C, Polentarutti N, Fruscella P, Ghezzi P, Faggioni R, Luini W, van Hinsbergh V, Sozzani S, Bussolino F, Poli V, Ciliberto G, Mantovani A: Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity 1997,6(3):315–325.PubMedView Article
- Ambrosini E, Aloisi F: Chemokines and glial cells: a complex network in the central nervous system. Neurochem Res 2004,29(5):1017–1038.PubMedView Article
- White FA, Jung H, Miller RJ: Chemokines and the pathophysiology of neuropathic pain. Proc Natl Acad Sci U S A 2007,104(51):20151–20158.PubMed CentralPubMedView Article
- Bhangoo SK, Ripsch MS, Buchanan DJ, Miller RJ, White FA: Increased chemokine signaling in a model of HIV1-associated peripheral neuropathy. Mol Pain 2009, 5: 48.PubMed CentralPubMedView Article
- Bhangoo SK, Ren D, Miller RJ, Chan DM, Ripsch MS, Weiss C, McGinnis C, White FA: CXCR4 chemokine receptor signaling mediates pain hypersensitivity in association with antiretroviral toxic neuropathy. Brain Behav Immun 2007,21(5):581–591.PubMed CentralPubMedView Article
- Wilson NM, Jung H, Ripsch MS, Miller RJ, White FA: CXCR4 signaling mediates morphine-induced tactile hyperalgesia. Brain Behav Immun 2011,25(3):565–573.PubMed CentralPubMedView Article
- Hur J, Sullivan KA, Pande M, Hong Y, Sima AA, Jagadish HV, Kretzler M, Feldman EL: The identification of gene expression profiles associated with progression of human diabetic neuropathy. Brain 2011,134(Pt 11):3222–3235.PubMed CentralPubMedView Article
- Miller RE, Tran PB, Das R, Ghoreishi-Haack N, Ren D, Miller RJ, Malfait AM: CCR2 chemokine receptor signaling mediates pain in experimental osteoarthritis. Proc Natl Acad Sci U S A 2012,109(50):20602–20607.PubMed CentralPubMedView Article
- Wright DE, Johnson MS, Arnett MG, Smittkamp SE, Ryals JM: Selective changes in nocifensive behavior despite normal cutaneous axon innervation in leptin receptor-null mutant (db/db) mice. J Peripher Nerv Syst 2007,12(4):250–261.PubMedView Article
- Oh SB, Tran PB, Gillard SE, Hurley RW, Hammond DL, Miller RJ: Chemokines and glycoprotein120 produce pain hypersensitivity by directly exciting primary nociceptive neurons. J Neurosci 2001,21(14):5027–5035.PubMed
- Woolf CJ, Ma Q: Nociceptors–noxious stimulus detectors. Neuron 2007,55(3):353–364.PubMedView Article
- Snider WD, McMahon SB: Tackling pain at the source: new ideas about nociceptors. Neuron 1998,20(4):629–632.PubMedView Article
- Basbaum AI, Bautista DM, Scherrer G, Julius D: Cellular and molecular mechanisms of pain. Cell 2009,139(2):267–284.PubMed CentralPubMedView Article
- Jung H, Bhangoo S, Banisadr G, Freitag C, Ren D, White FA, Miller RJ: Visualization of chemokine receptor activation in transgenic mice reveals peripheral activation of CCR2 receptors in states of neuropathic pain. J Neurosci 2009,29(25):8051–8062.PubMed CentralPubMedView Article
- Scholz J, Woolf CJ: The neuropathic pain triad: neurons, immune cells and glia. Nat Neurosci 2007,10(11):1361–1368.PubMedView Article
- Marchand F, Perretti M, McMahon SB: Role of the immune system in chronic pain. Nat Rev Neurosci 2005,6(7):521–532.PubMedView Article
- Obrosova IG, Ilnytska O, Lyzogubov VV, Pavlov IA, Mashtalir N, Nadler JL, Drel VR: High-fat diet induced neuropathy of pre-diabetes and obesity: effects of "healthy" diet and aldose reductase inhibition. Diabetes 2007,56(10):2598–2608.PubMedView Article
- LaMotte CC: Lamina X of primate spinal cord: distribution of five neuropeptides and serotonin. Neuroscience 1988,25(2):639–658.PubMedView Article
- Ma C, Shu Y, Zheng Z, Chen Y, Yao H, Greenquist KW, White FA, LaMotte RH: Similar electrophysiological changes in axotomized and neighboring intact dorsal root ganglion neurons. J Neurophysiol 2003,89(3):1588–1602.PubMedView Article
- Sun JH, Yang B, Donnelly DF, Ma C, LaMotte RH: MCP-1 enhances excitability of nociceptive neurons in chronically compressed dorsal root ganglia. J Neurophysiol 2006,96(5):2189–2199.PubMedView Article
- White FA, Sun J, Waters SM, Ma C, Ren D, Ripsch M, Steflik J, Cortright DN, Lamotte RH, Miller RJ: Excitatory monocyte chemoattractant protein-1 signaling is up-regulated in sensory neurons after chronic compression of the dorsal root ganglion. Proc Natl Acad Sci U S A 2005,102(39):14092–14097.PubMed CentralPubMedView Article
- Zhang N, Inan S, Cowan A, Sun R, Wang JM, Rogers TJ, Caterina M, Oppenheim JJ: A proinflammatory chemokine, CCL3, sensitizes the heat- and capsaicin-gated ion channel TRPV1. Proc Natl Acad Sci U S A 2005,102(12):4536–4541.PubMed CentralPubMedView Article
- Jung H, Toth PT, White FA, Miller RJ: Monocyte chemoattractant protein-1 functions as a neuromodulator in dorsal root ganglia neurons. J Neurochem 2008,104(1):254–263.PubMed CentralPubMed
- Marmigere F, Ernfors P: Specification and connectivity of neuronal subtypes in the sensory lineage. Nat Rev Neurosci 2007,8(2):114–127.PubMedView Article
- Breese NM, George AC, Pauers LE, Stucky CL: Peripheral inflammation selectively increases TRPV1 function in IB4-positive sensory neurons from adult mouse. Pain 2005,115(1–2):37–49.PubMedView Article
- Dirajlal S, Pauers LE, Stucky CL: Differential response properties of IB(4)-positive and -negative unmyelinated sensory neurons to protons and capsaicin. J Neurophysiol 2003,89(1):513–524.PubMedView Article
- Vincent AM, Callaghan BC, Smith AL, Feldman EL: Diabetic neuropathy: cellular mechanisms as therapeutic targets. Nat Rev Neurosci 2011,7(10):573–583.
- Kampoli AM, Tousoulis D, Briasoulis A, Latsios G, Papageorgiou N, Stefanadis C: Potential pathogenic inflammatory mechanisms of endothelial dysfunction induced by type 2 diabetes mellitus. Curr Pharm Des 2011,17(37):4147–4158.PubMedView Article
- Sjoholm A, Nystrom T: Endothelial inflammation in insulin resistance. Lancet 2005,365(9459):610–612.PubMedView Article
- Purwata TE: High TNF-alpha plasma levels and macrophages iNOS and TNF-alpha expression as risk factors for painful diabetic neuropathy. J Pain Res 2011, 4: 169–175.PubMed CentralPubMedView Article
- Uceyler N, Rogausch JP, Toyka KV, Sommer C: Differential expression of cytokines in painful and painless neuropathies. Neurology 2007,69(1):42–49.PubMedView Article
- Doupis J, Lyons TE, Wu S, Gnardellis C, Dinh T, Veves A: Microvascular reactivity and inflammatory cytokines in painful and painless peripheral diabetic neuropathy. J Clin Endocrinol Metab 2009,94(6):2157–2163.PubMed CentralPubMedView Article
- Galloway C, Chattopadhyay M: Increases in inflammatory mediators in DRG implicate in the pathogenesis of painful neuropathy in Type 2 diabetes. Cytokine 2013,63(1):1–5.PubMedView Article
- Sugimoto K, Yasujima M, Yagihashi S: Role of advanced glycation end products in diabetic neuropathy. Curr Pharm Des 2008,14(10):953–961.PubMedView Article
- Ramasamy R, Yan SF, Schmidt AM: Receptor for AGE (RAGE): signaling mechanisms in the pathogenesis of diabetes and its complications. Ann N Y Acad Sci 2011, 1243: 88–102.PubMed CentralPubMedView Article
- Ramasamy R, Yan SF, Schmidt AM: RAGE: therapeutic target and biomarker of the inflammatory response–the evidence mounts. J Leukoc Biol 2009,86(3):505–512.PubMedView Article
- Toth C, Martinez J, Zochodne DW: RAGE, diabetes, and the nervous system. Curr Mol Med 2007,7(8):766–776.PubMedView Article
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.